Oxford Biomedica Regulatory News (OXB)

4 Mar 2005 09:25

Oxford Biomedica PLC04 March 2005 FOR IMMEDIATE RELEASE 4 MARCH 2005 OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT Oxford, UK - 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading genetherapy company, today announces that Nick Woolf has been promoted to the Boardas an executive director. He will maintain his title of Senior Vice Presidentfor Corporate Strategy. His primary responsibilities include corporate finance,M&A evaluation and corporate communications as well as an important role,jointly with Peter Nolan, in business development and deal negotiation. Prior to joining Oxford BioMedica in 2002, Nick spent eight years as a top-ratedbiotechnology and pharmaceutical analyst. Nick has been involved in all aspectsof company financing, ranging from IPOs to major corporate deals. He served asDirector and Head of European Biotechnology Research at ABN AMRO, and waspreviously with Robertson Stephens International, Nomura and SBC Warburg. Nickholds an MA from Oxford University in Chemistry. Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive ofOxford BioMedica, said: "Nick has contributed at a very high level to allcorporate activities and has been instrumental in raising the Company's profilein the industry and the investment community. We are delighted to welcome him tothe Board." -Ends- For further information, please contact:Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000CommunicationsScientific/Trade Press Enquiries: Sue Charles/ Katja Stout/ Ashley Lilly Tel: +44 (0)20 7886 8150 Northbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical development in 2005, and fourfurther preclinical candidates. The Company is underpinned by over 80 patentfamilies, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,Viragen, MolMed and Kiadis; and has licensed technology to a number of companiesincluding Merck & Co and Biogen Idec. Further information is available at www.oxfordbiomedica.co.uk. This information is provided by RNS The company news service from the London Stock Exchange